文献速递MDS 与骨髓增殖性肿瘤

恩库林:源自血小板、巨核细胞及全血标本的骨髓增殖性肿瘤新型标志物

Enkurin: a novel marker for myeloproliferative neoplasms from platelet, megakaryocyte, and whole blood specimens.
PubMed 文献 · Blood Adv · 2023-01-01

研究利用MPN患者骨髓CD34+培养及健康脐带/外周血标本的离体与体外系统,在血小板、巨核细胞和全血中鉴定蛋白稳态相关标志物,发现恩库林(ENKUR)在MPN患者标本及实验模型中RNA和蛋白水平一致下调,并伴细胞周期标志物CDC20上调。

要点

  • 恩库林在MPN患者血小板、巨核细胞及全血标本中RNA和蛋白水平一致下调。
  • 恩库林下调伴随细胞周期标志物CDC20上调,CD34+来源巨核细胞中沉默ENKUR证实此关联。
  • 研究提示PI3K/Akt通路可能参与,恩库林为MPN发病机制的新型标志物。

核心结论

  • 恩库林是MPN发病机制的新型标志物,提示钙稳态失调及内质网与蛋白折叠应激在MPN转化中可能起作用,需进一步机制研究。

研究设计与样本

  • 研究采用离体与体外系统,包括MPN患者骨髓CD34+培养及健康脐带/外周血标本,延伸既往MPN患者血小板RNA测序数据。

主要发现

  • 在MPN患者血小板、亲本巨核细胞及全血标本中,恩库林在RNA和/或蛋白水平一致下调,实验模型(包括毒胡萝卜素处理)中同样下调。
  • 恩库林下调伴随细胞周期标志物CDC20上调。
  • CD34+来源巨核细胞中短发夹RNA沉默ENKUR,在RNA和蛋白水平进一步证实与CDC20的关联,并提示PI3K/Akt通路可能参与。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Impaired protein homeostasis, though well established in age-related disorders, has been recently linked with the pathogenesis of myeloproliferative neoplasms (MPNs). However, little is known about MPN-specific modulators of proteostasis, thus impeding our ability for increased mechanistic understanding and discovery of additional therapeutic targets. Loss of proteostasis, in itself, is traced to dysregulated mechanisms in protein folding and intracellular calcium signaling at the endoplasmic reticulum (ER). Here, using ex vivo and in vitro systems (including CD34+ cultures from patient bone marrow and healthy cord/peripheral blood specimens), we extend our prior data from platelet RNA sequencing in patients with MPN and discover select proteostasis-associated markers at RNA and/or protein levels in each of platelet, parent megakaryocyte, and whole blood specimens. Importantly, we identify a novel role in MPNs for enkurin (ENKUR), a calcium mediator protein originally implicated only in spermatogenesis. Our data reveal consistent ENKUR downregulation at both RNA and protein levels across specimens from patients with MPN and experimental models (including upon treatment with thapsigargin, an agent that causes protein misfolding in the ER by selective loss of calcium), with a concomitant upregulation of a cell cycle marker, CDC20. Silencing of ENKUR using short hairpin RNA in CD34+-derived megakaryocytes further confirms this association with CDC20 at both RNA and protein levels and indicates a likely role for the PI3K/Akt pathway. Together, our work sheds light on enkurin as a novel marker of MPN pathogenesis and indicates further mechanistic investigation into a role for dysregulated calcium homeostasis and ER and protein folding stress in MPN transformation.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Seetharam SM, Liu Y, Wu J, et al. Enkurin: a novel marker for myeloproliferative neoplasms from platelet, megakaryocyte, and whole blood specimens. Blood Adv. 2023. PMID: 37315179. doi:10.1182/bloodadvances.2022008939

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。